The present disclosure generally relates to compositions and techniques for treatment of vulvar and vaginal atrophy (VVA). In some embodiments, a composition comprising tamoxifen and/or pharmaceutically acceptable salts thereof. The composition may be applied intravaginally to a vagina of a subject. In addition, certain embodiments as described herein are generally directed to techniques for making or using such compositions, kits including such compositions, or the like.
The present disclosure generally relates to compositions and techniques for treatment of female sexual dysfunction (FSD), including female sexual arousal disorder (FSAD). In some embodiments, a composition such as a cream may be applied to the genital of a subject. The composition may also contain an active ingredient for treatment of FSD and/or FSAD, e.g., sildenafil, and/or pharmaceutically acceptable salts thereof. In addition, certain embodiments as described herein are generally directed to techniques for using such compositions, kits including such compositions, or the like.
A61K 31/519 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/4985 - Pyrazines ou pipérazines condensées en ortho ou en péri avec des systèmes hétérocycliques
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/506 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 31/53 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec trois azote comme seuls hétéro-atomes d'un cycle, p.ex. chlorazanil, mélamine
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur
A61P 15/00 - Médicaments pour le traitement des troubles génitaux ou sexuels; Contraceptifs
A61P 15/02 - Médicaments pour le traitement des troubles génitaux ou sexuels; Contraceptifs pour les pathologies du vagin
3.
COMPOSITIONS AND METHODS FOR TREATING DYSMENORRHEA
The present disclosure generally relates to compositions and techniques for treatment of dysmenorrhea using intravaginal delivery. In some embodiments, a composition such as a gel may be applied to the vagina of a subject that is relatively viscous, for example, with a viscosity at room temperature of at least 800,000 cP. The composition may also contain an active ingredient for treatment of dysmenorrhea (e.g., primary dysmenorrhea), e.g., diclofenac, and/or pharmaceutically acceptable salts thereof. In addition, certain embodiments as described herein are generally directed to techniques for making or using such compositions, kits including such compositions, or the like.
A61K 47/10 - Alcools; Phénols; Leurs sels, p.ex. glycérol; Polyéthylène glycols [PEG]; Poloxamères; Alkyléthers de PEG/POE
A61K 47/12 - Acides carboxyliques; Leurs sels ou anhydrides
A61K 47/36 - Polysaccharides; Leurs dérivés, p.ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
A61F 5/50 - Dispositifs pour empêcher la succion des doigts
A61F 6/06 - Dispositifs de contraception; Pessaires; Dispositifs pour les introduire à usage féminin
A61F 6/14 - Dispositifs de contraception; Pessaires; Dispositifs pour les introduire à usage féminin du type intra-utérin
A61K 31/196 - Acides carboxyliques, p.ex. acide valproïque ayant un groupe amino le groupe amino étant lié directement à un cycle, p.ex. acide anthranilique, acide méfénamique, diclofénac, chlorambucil
A61K 31/5575 - Eicosanoïdes, p.ex. leucotriènes ayant un cycle cyclopentane, p.ex. prostaglandine E2, prostaglandine F2-alpha
A61M 31/00 - Dispositifs pour l'introduction ou la rétention d'agents, p.ex. de remèdes, dans les cavités du corps
A61P 15/00 - Médicaments pour le traitement des troubles génitaux ou sexuels; Contraceptifs
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p.ex. agents antirhumatismaux; Médicaments anti-inflammatoires non stéroïdiens [AINS]
4.
COMPOSITIONS AND TECHNIQUES FOR TREATMENT OF POLYCYSTIC OVARIAN SYNDROME (PCOS) AND ENDOMETRIOSIS
The present disclosure generally relates to compositions and methods for treating polycystic ovarian syndrome (PCOS) and/or endometriosis. The composition may contain an active ingredient for treatment of PCOS and/or endometriosis, e.g., hydroxychloroquine, and/or salts thereof. In some embodiments, a composition such as a gel may be applied to the vagina of a subject that is relatively viscous, for example, with a viscosity at room temperature of at least 1.5 million cP. Compositions having such relatively high viscosities may be useful, for example, to prevent the composition from readily exiting the vagina or degrading too quickly. In some embodiments, a drug delivery device containing the active agent may be inserted in the vagina. In some embodiments, the drug delivery device is an intravaginal ring.
A61K 47/10 - Alcools; Phénols; Leurs sels, p.ex. glycérol; Polyéthylène glycols [PEG]; Poloxamères; Alkyléthers de PEG/POE
A61K 47/12 - Acides carboxyliques; Leurs sels ou anhydrides
A61K 47/36 - Polysaccharides; Leurs dérivés, p.ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
A61F 6/06 - Dispositifs de contraception; Pessaires; Dispositifs pour les introduire à usage féminin
A61F 6/14 - Dispositifs de contraception; Pessaires; Dispositifs pour les introduire à usage féminin du type intra-utérin
A61K 31/196 - Acides carboxyliques, p.ex. acide valproïque ayant un groupe amino le groupe amino étant lié directement à un cycle, p.ex. acide anthranilique, acide méfénamique, diclofénac, chlorambucil
A61K 31/5575 - Eicosanoïdes, p.ex. leucotriènes ayant un cycle cyclopentane, p.ex. prostaglandine E2, prostaglandine F2-alpha
A61M 31/00 - Dispositifs pour l'introduction ou la rétention d'agents, p.ex. de remèdes, dans les cavités du corps
A61P 15/00 - Médicaments pour le traitement des troubles génitaux ou sexuels; Contraceptifs
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p.ex. agents antirhumatismaux; Médicaments anti-inflammatoires non stéroïdiens [AINS]
Disclosed herein are intravaginal ring (IVR) devices comprising barriers that may be metal, polymeric or combinations of metal and polymeric. The IVRs are useful for contraception, treating and/or preventing sexually transmitted diseases, and treating and/or preventing bacterial infections. The IVR's are resistant to distortion due to absorption of vaginal fluids. This allows the IVRs to perform better over time as compared to other intravaginal rings made with copolymeric silicone.
The present disclosure generally relates to compositions and methods for treating polycystic ovarian syndrome (PCOS) and/or endometriosis. The composition may contain an active ingredient for treatment of PCOS and/or endometriosis, e.g., melatonin, a melatonin receptor agonist, and/or salts thereof. In some embodiments, a composition such as a gel may be applied to the vagina of a subject that is relatively viscous, for example, with a viscosity at room temperature of at least 1.5 million cP. Compositions having such relatively high viscosities may be useful, for example, to prevent the composition from readily exiting the vagina or degrading too quickly. In some embodiments, a drug delivery device containing the active agent may be inserted in the vagina. In some embodiments, the drug delivery device is an intravaginal ring.
A61K 31/196 - Acides carboxyliques, p.ex. acide valproïque ayant un groupe amino le groupe amino étant lié directement à un cycle, p.ex. acide anthranilique, acide méfénamique, diclofénac, chlorambucil
A61K 31/5575 - Eicosanoïdes, p.ex. leucotriènes ayant un cycle cyclopentane, p.ex. prostaglandine E2, prostaglandine F2-alpha
A61K 47/10 - Alcools; Phénols; Leurs sels, p.ex. glycérol; Polyéthylène glycols [PEG]; Poloxamères; Alkyléthers de PEG/POE
A61K 47/12 - Acides carboxyliques; Leurs sels ou anhydrides
A61K 47/36 - Polysaccharides; Leurs dérivés, p.ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
A61M 31/00 - Dispositifs pour l'introduction ou la rétention d'agents, p.ex. de remèdes, dans les cavités du corps
A61P 15/00 - Médicaments pour le traitement des troubles génitaux ou sexuels; Contraceptifs
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p.ex. agents antirhumatismaux; Médicaments anti-inflammatoires non stéroïdiens [AINS]
7.
METHODS AND DEVICES FOR HORMONE REPLACEMENT THERAPY
A drug delivery device for use in the treatment of one or more symptoms of menopause in a subject, comprising intravaginally inserting the implantable drug delivery device to the subject, wherein the implantable drug delivery device comprises an estrogen and a progestin, and further wherein the implantable drug delivery device provides a baseline-adjusted steady state plasma estrogen concentration between about 15 pg/mL and about 50 pg/mL in the subject.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/565 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrène; Leurs dérivés, p.ex. stéroïdes non substitués en position 17 bêta par un atome de carbone, p.ex. œstrane, œstradiol
A61K 31/57 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrène; Leurs dérivés, p.ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p.ex. prégnane ou progestérone
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. carbomères
The present disclosure generally relates to compositions and techniques for vaginal insertion. In some embodiments, a composition such as a gel may be applied to the vagina of a subject that is relatively viscous, for example, with a viscosity at room temperature of at least 1.5 million cP. The composition may also contain an active ingredient, e.g., dinoprostone, diclofenac, and/or salts thereof. Compositions having such relatively high viscosities may be useful, for example, to prevent the composition from readily exiting the vagina or degrading too quickly. This may, for example, allow the composition to release the active ingredient over a relatively long period of time to the vagina. In some embodiments, such compositions may be prepared by removing air from the composition to increase its viscosity or cause the composition to form a gel, etc. In addition, certain embodiments as described herein are generally directed to techniques for making or using such compositions, kits including such compositions, or the like.
A61K 31/196 - Acides carboxyliques, p.ex. acide valproïque ayant un groupe amino le groupe amino étant lié directement à un cycle, p.ex. acide anthranilique, acide méfénamique, diclofénac, chlorambucil
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/5575 - Eicosanoïdes, p.ex. leucotriènes ayant un cycle cyclopentane, p.ex. prostaglandine E2, prostaglandine F2-alpha
A61K 47/10 - Alcools; Phénols; Leurs sels, p.ex. glycérol; Polyéthylène glycols [PEG]; Poloxamères; Alkyléthers de PEG/POE
A61K 47/12 - Acides carboxyliques; Leurs sels ou anhydrides
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol o
A61K 47/36 - Polysaccharides; Leurs dérivés, p.ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
9.
SYSTEMS AND METHODS FOR TREATMENT OF BACTERIAL VAGINOSIS
A pharmaceutical composition for use in the treatment of bacterial vaginosis, wherein said composition comprises a poloxamer, a stabilization polymer, and an active ingredient for treating the bacterial vaginosis, preferably clindamycin, wherein said composition has a viscosity of at least 1.5 million mPa·s.
A61K 31/7056 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p.ex. nucléosides, nucléotides contenant des cycles à cinq chaînons avec l'azote comme hétéro-atome d'un cycle
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A pharmaceutical composition for use in the treatment of bacterial vaginosis, wherein said composition comprises a poloxamer, a stabilization polymer, and an active ingredient for treating the bacterial vaginosis, preferably clindamycin, wherein said composition has a viscosity of at least 1.5 million mPa.s.
A61K 31/7056 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p.ex. nucléosides, nucléotides contenant des cycles à cinq chaînons avec l'azote comme hétéro-atome d'un cycle
A61K 47/10 - Alcools; Phénols; Leurs sels, p.ex. glycérol; Polyéthylène glycols [PEG]; Poloxamères; Alkyléthers de PEG/POE
A61P 15/02 - Médicaments pour le traitement des troubles génitaux ou sexuels; Contraceptifs pour les pathologies du vagin
A pharmaceutical composition for use in the treatment of bacterial vaginosis, wherein said composition comprises a poloxamer, a stabilization polymer, and an active ingredient for treating the bacterial vaginosis, preferably clindamycin, wherein said composition has a viscosity of at least 1.5 million mPa.s.
A61K 31/7056 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p.ex. nucléosides, nucléotides contenant des cycles à cinq chaînons avec l'azote comme hétéro-atome d'un cycle
A61P 15/02 - Médicaments pour le traitement des troubles génitaux ou sexuels; Contraceptifs pour les pathologies du vagin
A composition, comprising a poloxamer, a stabilization polymer, and diclofenac as an active ingredient suitable for treating dysmenorrhea, wherein the composition has a viscosity at room temperature of at least 1.5 million cP.
A61K 31/196 - Acides carboxyliques, p.ex. acide valproïque ayant un groupe amino le groupe amino étant lié directement à un cycle, p.ex. acide anthranilique, acide méfénamique, diclofénac, chlorambucil
A61K 31/5575 - Eicosanoïdes, p.ex. leucotriènes ayant un cycle cyclopentane, p.ex. prostaglandine E2, prostaglandine F2-alpha
A61K 47/10 - Alcools; Phénols; Leurs sels, p.ex. glycérol; Polyéthylène glycols [PEG]; Poloxamères; Alkyléthers de PEG/POE
A61K 47/12 - Acides carboxyliques; Leurs sels ou anhydrides
A61K 47/36 - Polysaccharides; Leurs dérivés, p.ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
A61P 15/00 - Médicaments pour le traitement des troubles génitaux ou sexuels; Contraceptifs
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p.ex. agents antirhumatismaux; Médicaments anti-inflammatoires non stéroïdiens [AINS]
13.
COMPOSITIONS FOR USE IN THE TREATMENT OF DYSMENORRHEA
A composition, comprising a poloxamer, a stabilization polymer, and diclofenac as an active ingredient suitable for treating dysmenorrhea, wherein the composition has a viscosity at room temperature of at least 1.5 million cP.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/10 - Alcools; Phénols; Leurs sels, p.ex. glycérol; Polyéthylène glycols [PEG]; Poloxamères; Alkyléthers de PEG/POE
A61K 31/196 - Acides carboxyliques, p.ex. acide valproïque ayant un groupe amino le groupe amino étant lié directement à un cycle, p.ex. acide anthranilique, acide méfénamique, diclofénac, chlorambucil
A61K 31/5575 - Eicosanoïdes, p.ex. leucotriènes ayant un cycle cyclopentane, p.ex. prostaglandine E2, prostaglandine F2-alpha
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p.ex. agents antirhumatismaux; Médicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 15/00 - Médicaments pour le traitement des troubles génitaux ou sexuels; Contraceptifs
Disclosed herein are intravaginal ring (IVR) devices comprising barriers that may be metal, polymeric or combinations of metal and polymeric. The IVRs are useful for contraception, treating and/or preventing sexually transmitted diseases, and treating and/or preventing bacterial infections. The IVR's are resistant to distortion due to absorption of vaginal fluids. This allows the IVRs to perform better over time as compared to other intravaginal rings made with copolymeric silicone.
Disclosed herein are intravaginal ring (IVR) devices comprising barriers that may be metal, polymeric or combinations of metal and polymeric. The IVRs are useful for contraception, treating and/or preventing sexually transmitted diseases, and treating and/or preventing bacterial infections. The IVR's are resistant to distortion due to absorption of vaginal fluids. This allows the IVRs to perform better over time as compared to other intravaginal rings made with copolymeric silicone.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the treatment and prevention
of bacterial infections; antibiotic topical preparations;
pharmaceutical preparations for treating bacterial
vaginosis.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Pharmaceutical preparations for the treatment and prevention of bacterial vaginal infections; antibiotic topical preparations; pharmaceutical preparations for treating bacterial vaginosis
Disclosed herein are intravaginal ring (IVR) devices comprising barriers that may be metal, polymeric or combinations of metal and polymeric. The IVRs are useful for contraception, treating and/or preventing sexually transmitted diseases, and treating and/or preventing bacterial infections. The IVR's are resistant to distortion due to absorption of vaginal fluids. This allows the IVRs to perform better over time as compared to other intravaginal rings made with copolymeric silicone.
Disclosed herein are intravaginal ring devices that are resistant to distortion due to absorption of vaginal fluids. This allows the rings to perform better over time as compared to other intravaginal rings made with copolymeric silicone.
Disclosed herein are intravaginal ring devices that are resistant to distortion due to absorption of vaginal fluids. This allows the rings to perform better over time as compared to other intravaginal rings made with copolymeric silicone.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the treatment and prevention of bacterial infections; Antibiotic topical preparations; pharmaceutical preparations for treating bacterial vaginosis
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
Produits et services
Contraceptive preparations Medical products, namely, a polymer intra-vaginal ring with an incorporated mesh insert that is designed to reside in the vaginal fornix, essentially covering the external orifice of the cervix, and medical devices and contraceptive apparatuses for vaginal and intrauterine contraception
This invention relates to a method and pharmaceutical composition useful in treating a condition responsive to hormone replacement therapy. Specifically, the invention is related to the long term treatment of symptoms associated with atrophic vaginitis. The composition contains effective amounts of an estrogen, a progesterone compound and a pharmaceutically accepted vehicle, carrier and/or diluent.
